{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:05:02Z","timestamp":1772503502822,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000723","name":"Tenovus","doi-asserted-by":"publisher","award":["T11\/22"],"award-info":[{"award-number":["T11\/22"]}],"id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To test the hypothesis that dipeptidyl peptidase\u20104 inhibition in C\u2010peptide negative Type 1 diabetes would reduce glucose variability and exposure to hypoglycaemia and therefore may indirectly enhance counter\u2010regulatory responses to subsequent hypoglycaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a 12\u2010week double\u2010blind, randomized, placebo\u2010controlled crossover study. The study was conducted in a tertiary hospital outpatient clinic, with additional studies performed in a clinical research centre. After obtaining informed consent, we recruited 14 subjects with moderately well controlled Type 1 diabetes (HbA<jats:sub>1c<\/jats:sub> 64 \u00b1 2 mmol\/mol) of long duration (20.5 \u00b1 2.7 years). The subjects received 12 weeks' therapy with oral saxagliptin (5 mg) or placebo. Glucose variability, assessed via continuous glucose monitoring, together with frequency of hypoglycaemia, hypoglycaemia awareness and symptomatic, cognitive and counter\u2010regulatory hormone responses to experimental hypoglycaemia, were assessed. Additional outcome measures included HbA<jats:sub>1c<\/jats:sub> level, weight, total daily insulin dose and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Saxagliptin co\u2010therapy did not reduce glucose variability (low blood glucose index, average daily risk range), hypoglycaemia frequency or awareness and did not improve counter\u2010regulatory hormonal responses during experimental hypoglycaemia (area under the curve for adrenaline 25 775 vs. 24 454, for placebo vs saxagliptin, respectively; <jats:italic>P<\/jats:italic> = 0.76).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No additional benefit of dipeptidyl peptidase\u20104 inhibition co\u2010therapy with saxagliptin in the management of Type 1 diabetes was observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.13046","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T18:29:28Z","timestamp":1449599368000},"page":"1283-1290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Saxagliptin co\u2010therapy in C\u2010peptide negative Type 1 diabetes does not improve counter\u2010regulatory responses to hypoglycaemia"],"prefix":"10.1111","volume":"33","author":[{"given":"P. S.","family":"George","sequence":"first","affiliation":[{"name":"Cardiovascular and Diabetes Medicine School of Medicine University of Dundee Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"McCrimmon","sequence":"additional","affiliation":[{"name":"Cardiovascular and Diabetes Medicine School of Medicine University of Dundee Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0113"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0123"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.12.1397"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02413.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03744.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.49"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.182.4108.171"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2004.06.003"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.03.004"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.6.626"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03331.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2332"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.7.697"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0247"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1655"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1085"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.11.1870"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401150"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15324826AN0902_5"},{"key":"e_1_2_9_22_1","volume-title":"Manual for the Wechsler Adult Intelligence Scale Revised","author":"Wechsler D","year":"1981"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.7.901"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91336-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.11.1683"},{"key":"e_1_2_9_26_1","first-page":"jc20152725","article-title":"The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight from the LIBRA Trial","author":"Kramer CK","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP12100.OR"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13046","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:12:06Z","timestamp":1696302726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/dme.13046"],"URL":"https:\/\/doi.org\/10.1111\/dme.13046","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,28]]},"assertion":[{"value":"2015-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}